Inactive

Request for Limited Sources Justification Format >SAT VHAPG Part 808.405-6 Limiting Sources Page 1 of 4 Revision: 01 Effective Date: 09/01/2024 Acquisition ID#: 36C262-26-AP-0853 LIMITED SOURCES JUSTI... Request for Limited Sources Justification Format >SAT VHAPG Part 808.405-6 Limiting Sources Page 1 of 4 Revision: 01 Effective Date: 09/01/2024 Acquisition ID#: 36C262-26-AP-0853 LIMITED SOURCES JUSTIFICATION ORDER >SAT FAR PART 8.405-6 Acquisition Plan Action ID: 36C262-26-AP-0853 (1) Contracting Activity Department of Veterans Affairs (VA), Network/Program Contracting Office 22, located at 4811 Airport Plaza Drive Long Beach, CA 90815, in support of VISN 22 VA Long Beach Health Care System at 5901 East 7th Street Long Beach, CA 90822. PR# 600-26-1-114-0004 (2) Description of Action: This acquisition is conducted under the authority of the Multiple-Award Schedule Program (41 U.S.C. 152(3) and 40 U.S.C. 501). This requirement for Pylarify will be awarded as a new requirement as a base plus two option year delivery order against National Acquisition Center (NAC) Federal Supply Schedule (FSS) contract 36F79725D0093. Order against: FSS Contract Number: 36F79725D0093 Name of Proposed Contractor: Progenics Pharmaceuticals, Inc. Street Address: 331 Treble Cove Road City, State, Zip: N. Billerica, MA 01862 Phone: 414-336-9169 (3) Description of Supplies or Services: The estimated value of the proposed action is $1,082,616.00 Pylarify (piflufolastat F 18) Injection National Drug Code (NDC): 71258-0022-01 is an advanced diagnostic imaging agent used with Positron Emission Tomography (PET)/Computed Tomography (CT) scans to find tumors in the prostate which identify the prostate-specific membrane antigen (PSMA), as well as in lymph nodes, bones, and other organs. Veterans Affairs (VA) Long Beach Healthcare System s Nuclear Medicine Department is requesting a base year delivery order due to the current and foreseen requirement for this radiopharmaceutical to support with streamlining future orders. The delivery order required is: Delivery Order Description Unit Price Quantity Unit of Measure Obligated Funding Base 11/1/2025 10/31/2026 Pylarify $3,608.72 300 EA $1,082,616.00 TOTAL $1,082,616.00 (4) Identify the Authority and Supporting Rationale (see below and if applicable, a demonstration of the proposed contractor s unique qualifications to provide the required supply or service. FAR 8.405-6(a)(1)(A): An urgent and compelling need exists and following the ordering procedures would result in unacceptable delays: FAR 8.405-6(a)(1)(B): Only one source is capable of providing the supplies or services required at the level of quality required because the supplies or services are unique or highly specialized; Pylarify binds to prostate-specific membrane antigen (PSMA), which is an important pharmacologic target for prostate cancer imaging because prostate cancer cells usually contain elevated levels of the antigen. As a radioactive drug that emits positrons, Pylarify can be imaged by PET to indicate the presence of the PSMA-positive prostate cancer lesions in the tissues of the body. Currently, there are no other equivalent treatments available in the United States. The NAC has contracted with the only authorized manufacturer of the medication, Progenics pharmaceuticals, Inc. under FSS contract number 36F79725D0093. The vendor has provided a letter stating that they are the sole manufacturer and authorized supplier . There is only one vendor listed on the NAC Pharmaceutical website that can provide this medication due to the proprietary and highly specialized nature of this medication. FAR 8.405-6(a)(1)(C): In the interest of economy and efficiency, the new work is a logical follow-on to an original Federal Supply Schedule order provided that the original order was placed in accordance with the applicable Federal Supply Schedule ordering procedures. The original order must not have been previously issued under sole source or limited source procedures. FAR 8.405-6(b): Items peculiar to one manufacturer: A patent, copyright or proprietary data limits competition. The proprietary data is: These are direct replacements parts/components for existing equipment. The material/service must be compatible in all aspects (form, fit and function) with existing systems presently installed/performing. (5) Describe Why You Believe the Order Represents the Best Value consistent with FAR 8.404(d) to aid the contracting officer in making this best value determination: This order represents best value to the government since the NAC has already negotiated the best price for the government. The radiopharmaceutical market fluctuates constantly, and it is in the best interest of the government to contract with the manufacturer, Progenics Pharmaceuticals, Inc. with the agreed upon cost of the proprietary and highly specialized medication, Pylarify at $3,774.94 per injection. Network Contracting Office (NCO) 22 did seek further discounts to this order in which the vendor, Progenics, agreed to keep pricing at the prior listed contract pricing at $3,608.72 for the delivery order. (6) Describe the Market Research Conducted among schedule holders and the results or a statement of the reason market research was not conducted. A search of the NAC Pharmaceutical website was conducted, which returned the required pharmaceutical, Pylarify, listed under contract 36F79725D0093 awarded to Progenics Pharmaceuticals, Inc. Federal Procurement Data System (FPDS) was also searched to identify prior acquisitions for the medication, as well as a search of the world wide web to determine if other medications like Pylarify are available in the United States. The results from FPDS returned multiple delivery orders against NAC FSS contract 36F79725D0093 awarded by multiple NCOs. The search of the worldwide web returned no equal to products. Due to the specialized nature of this drug, it is not available from any other vendor. There is currently no therapeutically equivalent version of Pylarify available in the United States. The medication, Pylarify, is a radiopharmaceutical and subject to the requirements outlined by the Food and Drug Administration (FDA). The delivery of this medication is subject to the terms outlined in the Department of Transportation (DoT) and all local and state requirements. Pylarify is on FSS NAC contract 36F79725D0093 awarded to Progenics Pharmaceuticals, Inc. priced at $3,712.78 per injection. The contract 36F79725D0093 for Pylarify was effective 4/1/2025 and expires 3/31/2030. The market research was conducted from 3/15/2025 10/10/2025 (7) Any Other Facts Supporting the Justification: Lantheus owns Progenics Pharmaceuticals, Inc. (8) A Statement of the Actions, if any, the agency may take to remove or overcome any barriers that led to the restricted consideration before any subsequent acquisition for the supplies or services is made: The Department of Veteran Affairs will continue to survey the marketplace for equal to or better therapies that will offer veterans the most up to date care. (9) Requirements Certification: I certify that the requirement outlined in this justification is a Bona Fide Need of the Department of Veterans Affairs and that the supporting data under my cognizance, which are included in the justification, are accurate and complete to the best of my knowledge. I understand that processing of this limited sources justification restricts consideration of Federal Supply Schedule contractors to fewer than the number required by FAR Subpart 8.4. _____ Edward Fua DATE Lead Nuclear Medicine Technician VA Long Beach Healthcare System (10) Approvals in accordance with the VHAPM Part 806.3 OFOC SOP: a. Contracting Officer s Certification (required): I certify that the foregoing justification is accurate and complete to the best of my knowledge and belief. _____ Adrienne Brown, Contracting Officer DATE Supply 4 NCO 22 b. One Level Above the Contracting Officer (Required over the SAT but not exceeding $750K): I certify the justification meets requirements for other than full and open competition. _____ Peter Kim DATE Supply 4, Branch Chief NCO 22 ____________________________________ __________________________________ Sabrina Smith DATE Director of Contracting NCO 22 HIGHER LEVEL APPROVAL (Required for orders over $750,000): c. VHA RPO HCA Review and Approval (over $750,000 to $75 million): I have reviewed the foregoing justification and find it to be complete and accurate to the best of my knowledge and belief and approve for restricting consideration of the Federal Supply Schedule contractors to fewer than the number required by FAR Subpart 8.4. ____________________________________ ______________________________ Curtis M. Jordan DATE Executive Director, Regional Procurement Office West Head of Contracting Activity (HCA)